SMFM 27th Annual Meeting 2007
view the interview video: Advanced Maternal Age and Risk of Intrauterine Fetal Death
Abstract
Objective: AMA is associated with an increased risk of complications of pregnancy, such as gestational diabetes, preeclampsia, and placenta previa. Antepartum surveillance has reduced intruterine fetal death (IUFD) rates in some circumstances. We sought to determine if AMA was an independent predictor of IUFD, and if so, at what maternal age antenatal testing may have the greatest impact.
Study Design: We conducted a cross-sectional study using US CDC perinatal mortality data from 1995-1997 comprised of 11,061,599 singleton deliveries. Women from 15 to 44 years of age with term (≥ 37 weeks), singleton pregnancies were included in the analysis. Cox proportional hazards models and logistic regression analysis were used for relative risk estimation and 95% confidence interval (CI) calculation. Number needed to treat (NNT) was calculated based on known IUFD rates, on the assumption that antenatal testing would reduce the risk of IUFD to that of the referent group.
Results: After excluding congenital anomalies and maternal medical complications, 6,239,399 singleton, term deliveries were identified. When compared to the referent group (maternal age 25 to 29), the risk of IUFD increased with advancing maternal age: 30 to 34 RR = 1.24 (95% CI, 1.13-1.36); 35 to 39 RR = 1.45 (95% CI, 1.21-1.74), and 40 to 44 RR = 3.04 (95% CI, 1.58-5.86). Time to event analysis indicated that the risk of IUFD significantly increased beginning at 38 weeks gestation. Our model suggests that for ages 35 to 39, initiation of fetal testing at 38 weeks of gestation would require approximately 3126 women to have antepartum surveillance to prevent one IUFD, as opposed to only 553 tests for maternal age 40 to 44 years.
Conclusion: AMA is an independent risk factor for IUFD. The cumulative risk of IUFD at 38 weeks of gestation in an uncomplicated patient age 40 and over is similar to the risk of IUFD at 41 weeks in an uncomplicated patient less than age 35. These results support routine antenatal testing beginning at maternal age 40, and started at 38 weeks gestation.
0002-9378/$ - see front matter
doi:10.1016/j.ajog.2006.10.753
American Journal of Obstetrics and Gynecology
Volume 195, Issue 6, Supplement S (December 2006)
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More